These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17003368)

  • 21. Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia.
    Aoki Y; Watanabe T; Saito Y; Kuroki Y; Hijikata A; Takagi M; Tomizawa D; Eguchi M; Eguchi-Ishimae M; Kaneko A; Ono R; Sato K; Suzuki N; Fujiki S; Koh K; Ishii E; Shultz LD; Ohara O; Mizutani S; Ishikawa F
    Blood; 2015 Feb; 125(6):967-80. PubMed ID: 25538041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Childhood T-cell acute lymphoblastic leukemia with four distinct immunophenotypes representing different stages of T-cell development.
    Miura T; Ouhira M; Koseki N; Obara Y; Fujimaki S; Imaizumi M; Kameoka J; Sasaki T; Funato T; Harigae H; Kaku M
    Pediatr Hematol Oncol; 2001 Jun; 18(4):267-72. PubMed ID: 11400651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood.
    Dialynas DP; Shao L; Billman GF; Yu J
    Stem Cells; 2001; 19(5):443-52. PubMed ID: 11553853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
    Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD133 (AC133) expression on AML cells and progenitors.
    Vercauteren SM; Sutherland HJ
    Cytotherapy; 2001; 3(6):449-59. PubMed ID: 11953029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient.
    Piacibello W; Bruno S; Sanavio F; Droetto S; Gunetti M; Ailles L; Santoni de Sio F; Viale A; Gammaitoni L; Lombardo A; Naldini L; Aglietta M
    Blood; 2002 Dec; 100(13):4391-400. PubMed ID: 12453876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome.
    Woiterski J; Ebinger M; Witte KE; Goecke B; Heininger V; Philippek M; Bonin M; Schrauder A; Röttgers S; Herr W; Lang P; Handgretinger R; Hartwig UF; André MC
    Int J Cancer; 2013 Oct; 133(7):1547-56. PubMed ID: 23526331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias.
    Morisot S; Wayne AS; Bohana-Kashtan O; Kaplan IM; Gocke CD; Hildreth R; Stetler-Stevenson M; Walker RL; Davis S; Meltzer PS; Wheelan SJ; Brown P; Jones RJ; Shultz LD; Civin CI
    Leukemia; 2010 Nov; 24(11):1859-66. PubMed ID: 20739953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunophenotype of acute lymphoblastic leukemia cells: the experience of the Italian Cooperative Group (Gimema).
    De Rossi G; Grossi C; Foà R; Tabilio A; Vègna L; Lo Coco F; Annino L; Camera A; Cascavilla N; Ciolli S
    Leuk Lymphoma; 1993 Feb; 9(3):221-8. PubMed ID: 8471981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo.
    Blair A; Hogge DE; Ailles LE; Lansdorp PM; Sutherland HJ
    Blood; 1997 May; 89(9):3104-12. PubMed ID: 9129012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Good engraftment of B-cell precursor ALL in NOD-SCID mice.
    Baersch G; Möllers T; Hötte A; Dockhorn-Dworniczak B; Rübe C; Ritter J; Jürgens H; Vormoor J
    Klin Padiatr; 1997; 209(4):178-85. PubMed ID: 9293448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ; Warnes SL; Noss AL; Flavell SU
    Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia.
    Karawajew L; Ruppert V; Wuchter C; Kösser A; Schrappe M; Dörken B; Ludwig WD
    Blood; 2000 Jul; 96(1):297-306. PubMed ID: 10891465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
    Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
    Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
    Möbest D; Goan SR; Junghahn I; Winkler J; Fichtner I; Hermann M; Becker M; de Lima-Hahn E; Henschler R
    Stem Cells; 1999; 17(3):152-61. PubMed ID: 10342558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
    Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
    Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.
    Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM
    J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinically relevant expansion of hematopoietic stem cells with conserved function in a single-use, closed-system bioprocess.
    Madlambayan GJ; Rogers I; Purpura KA; Ito C; Yu M; Kirouac D; Casper RF; Zandstra PW
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1020-30. PubMed ID: 17084368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early-acting cytokine-driven ex vivo expansion of mobilized peripheral blood CD34+ cells generates post-mitotic offspring with preserved engraftment ability in non-obese diabetic/severe combined immunodeficient mice.
    Herrera C; Sánchez J; Torres A; Bellido C; Rueda A; Alvarez MA
    Br J Haematol; 2001 Sep; 114(4):920-30. PubMed ID: 11564087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia.
    Stevanović S; Griffioen M; Nijmeijer BA; van Schie ML; Stumpf AN; Rutten CE; Willemze R; Falkenburg JH
    Leukemia; 2012 Feb; 26(2):312-22. PubMed ID: 21860431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.